Screening method for pancreatic cancer adaptation disease extension of antitumor drugs

Through open source databases and high-throughput detection technology, identify specific targets of pancreatic cancer populations, screen out drugs with potential therapeutic effects, solve the problems of drug resistance and slow progress in pancreatic cancer treatment, and achieve support for personalized treatment and improve clinical results.

CN119069031APending Publication Date: 2024-12-03SOUTHEAST UNIV NANJING INST OF BIOMATERIALS & MEDICAL DEVICES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411119972.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing pancreatic cancer treatment methods have problems such as drug resistance, serious side effects and slow progress in drug development, and the lack of markers for characteristic markers and drug sensitivity related to pancreatic cancer populations, making it difficult to achieve personalized treatment.

Method used

Through bioinformatics analysis based on open source databases and high-throughput drug sensitivity detection, specific targets of pancreatic cancer populations are identified, drug-to-target affinity prediction is carried out, alternative drugs are screened out, and organoid high-throughput is performed by simulation experiments. Drug sensitivity testing to verify the actual sensitivity of the drug and related markers.

Benefits of technology

实现了胰腺癌群体特异性靶点的发现,快速筛选出具有潜在治疗效果的药物,降低了药物研发成本和时间,提供了个性化治疗的依据,提高了临床治疗效果。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119069031A_ABST
    Figure CN119069031A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of drug screening, in particular to a screening method for pancreatic cancer adaptation disease extension of anti-tumor drugs. The method comprises the following steps: screening pancreatic cancer markers and identifying targets on the basis of an open source database; drug and target affinity prediction is carried out based on the screened pancreatic cancer markers and targets; performing a simulation experiment on the predicted drug molecules with relatively high affinity; alternative drug molecules with high affinity are screened out according to experimental results; carrying out organoid high-throughput drug sensitivity detection on the screened alternative drug molecules; the medicine molecules with the effect are obtained. Potential drug targets with group specificity can be accurately screened out, and support is provided for pancreatic cancer adaptation disease expansion of drugs; a non-pancreatic cancer drug aiming at a newly screened target spot is accurately predicted, and high-throughput drug sensitivity detection is carried out to verify the actual sensitivity of the drug; the biomarker highly related to drug sensitivity is screened out, and a basis is provided for personalized treatment of pancreatic cancer by drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug screening, and in particular to a screening method for expanding the indication of pancreatic cancer of anti-tumor drugs. Background Art

[0002] Pancreatic cancer (CRC) is one of the malignant tumors with the highest morbidity and mortality rates worldwide. Although there are currently a variety of treatments, including surgery, radiotherapy, chemotherapy and targeted therapy, the clinical treatment effect is still unsatisfactory due to the heterogeneity of pancreatic cancer and drug resistance. Currently, the types of drugs used to treat pancreatic cancer are relatively limited, mainly including gemcitabine, capecitabine, FOLFIRINOX, fluorouracil, albumin paclitaxel, etc. These drugs have improved the survival rate and quality of life of pancreatic cancer patients to a certain extent, but there are still many problems, such as drug resistance, serious side effects, etc., and there is still a lack of effective drug options for all patients. In addition, the slow progress of drug research and development is mainly affected by multiple factors, including the complexity of the disease itself, the long drug development cycle, high cost, and high failure rate of clinical trials.

[0003] In order to solve the problem of drug treatment for the clinical pancreatic cancer patient group, commonly used methods include: cross-indication medication, personalized precision medicine, etc., but there will be many problems in the actual implementation process. For example, some drugs may have wide applicability to different types of cancer and have the feasibility of cross-indication drug use, but lack scientific basis for use; personalized treatment plans based on the genetic and molecular characteristics of patients are commonly used in clinical practice, but false positive assessments often occur due to the single drug sensitivity detection index or lack of marker basis. At present, the development of new drugs for pancreatic cancer is mainly based on traditional drug discovery and development models. Due to the huge number of molecules that can be used as candidate drugs, finding valuable candidate drugs is like looking for a needle in a haystack, which requires a lot of time and financial costs. In addition, the diversity of molecular subtypes of pancreatic cancer also increases the difficulty of effective drug development, resulting in slow progress in the development of targeted drugs. Summary of the invention

[0004] The purpose of the present invention is to address the problems existing in the background technology and propose a screening method for expanding the pancreatic cancer indications of anti-tumor drugs; it can accurately screen out potential drug targets with population specificity, thereby providing support for the expansion of the drug's pancreatic cancer indications; accurately predict non-pancreatic cancer drugs targeting newly screened targets, and perform high-throughput drug sensitivity testing to verify the actual sensitivity of the drug; screen out biomarkers that are highly correlated with drug sensitivity, providing a basis for personalized drug treatment of pancreatic cancer.

[0005] The technical solution of the present invention is a screening method for expanding the indication of pancreatic cancer of anti-tumor drugs, comprising the following specific steps:

[0006] S1. Screening of pancreatic cancer markers and target identification based on open source databases;

[0007] S2. Predict drug-target affinity based on the screened pancreatic cancer markers and targets;

[0008] S3. Conduct simulation experiments on the drug molecules with higher predicted affinity;

[0009] S4. Screen out candidate drug molecules with higher affinity based on the experimental results;

[0010] S5. Conduct high-throughput drug sensitivity testing in organoids on the candidate drug molecules screened in S4;

[0011] S6. Obtain effective drug molecules.

[0012] In an optional embodiment, step S1 identifies new potential drug targets for pancreatic cancer populations based on open source databases through bioinformatics analysis, drug sensitivity association analysis and functional annotation.

[0013] Preferably, bioinformatics analysis includes gene mutation analysis and gene expression analysis.

[0014] In an optional embodiment, step S1 further includes:

[0015] S11. Data collection: referring to the types of alternative drugs (alkylating drugs, anti-metabolites, antibiotics, plants, hormones, platinum compounds, targeted drugs, etc.), the standard indications of the selected drugs do not include pancreatic cancer, and the drug sensitivity test data (IC50 value), blood drug concentration data (Cmax value) and genetic data (gene mutation and gene expression) of pancreatic cancer cell lines that have completed drug sensitivity testing of relevant types are collected. The drug sensitivity test data are derived from the GDSC database (https: / / www.cancerrxgene.org / ), the maximum blood drug concentration (Cmax value) of the drug is derived from the DrugBank database (https: / / go.drugbank.com / ), and the gene mutation data and gene expression data of the corresponding cell lines are derived from the CMP database (https: / / cellmodelpassports.sanger.ac.uk / ).

[0016] In addition, the characteristic gene mutation data and copy number variation data of pancreatic cancer population were derived from the TCGA database (https: / / portal.gdc.cancer.gov / ), and the gene expression data of normal intestinal cells were derived from the THPA database (https: / / www.proteinatlas.org / )

[0017] S12. Bioinformatics analysis: Use dplyr to screen high-frequency gene mutations, use functional prediction tools (such as SIFT and PolyPhen) to evaluate the impact of mutations on gene function, and screen genes related to tumorigenesis for association analysis;

[0018] Use DESeq2 or edgeR to perform differential expression analysis to compare the gene expression differences between pancreatic cancer samples and normal samples. Combine the gene expression in normal cells and the copy number variation in the TCGA database to determine the gene expression (low expression or high expression) for association analysis;

[0019] S13, association analysis; integrate the genetic data of the sensitive sample group and the drug-resistant sample group, analyze the correlation through Fisher's exact test, and screen out mutant genes and abnormally expressed genes associated with drug sensitivity. Use linear correlation analysis to analyze the Pearson correlation coefficient of drug sensitivity data with variables such as mutant genes and abnormally expressed genes, and identify genes most prominently associated with drug sensitivity as potential drug targets. Use multiple test correction (such as Bonferroni or FDR) to control the false discovery rate;

[0020] S14. Functional annotation: Use Ensembl and RefSeq to perform functional annotation on differentially expressed genes and mutated genes, refer to the characteristic gene mutation data and copy number variation data of pancreatic cancer population, identify the role and potential mechanism of these genes in tumorigenesis, prioritize them based on association analysis data, and screen out new potential drug targets.

[0021] In an optional embodiment, the types of referenced candidate drugs include alkylating drugs, anti-metabolites, antibiotics, plants, hormones, platinum compounds, and targeted drugs.

[0022] In an optional embodiment, step S2 further includes:

[0023] S21. Data collection: According to the drug target name, the three-dimensional structure of the target protein is obtained from the PDB database (https: / / www.rcsb.org / ) or through homology modeling and other methods.

[0024] According to the candidate drug names, the three-dimensional structures of drug molecules were obtained from the Pubchem database (https: / / pubchem.ncbi.nlm.nih.gov / );

[0025] S22. Data preprocessing; Protein preprocessing: Use AutoDockTools (ADT) to open the protein PDB file, add missing hydrogen atoms, and repair missing side chains and residues; unless water molecules play an important role in the binding pocket, water molecules generally need to be deleted; add polar hydrogen atoms to the protein; if flexible docking is required, select the flexible chain in the protein.

[0026] Pretreatment of drug molecules: Use chemical software (such as Chem3D) to optimize the geometry of the ligand and generate low-energy conformations; add polar hydrogen atoms to the ligand; define rotatable bonds in the ligand to simulate the flexibility of the ligand during docking

[0027] S23. Molecular docking; Define docking sites: Identify active sites or target regions in proteins, either through known ligand binding sites or structure-based predictions.

[0028] Set docking parameters: Set docking parameters according to the selected software, including docking mode, search algorithm, scoring function, etc.;

[0029] Run docking calculations: dock drug molecules into protein targets, generate multiple docking conformations and scores;

[0030] S24. Result analysis; Evaluation of docking results: Evaluate the affinity between the drug and the target based on the docking scoring function and select the conformation with a higher score.

[0031] Visualization analysis: Use visualization software (such as Chimera, PyMOL) to analyze the docking results and examine the interaction patterns between drugs and targets, such as hydrogen bonding, hydrophobic interactions, π-π stacking, etc.

[0032] Energy minimization: Minimize the energy of the optimal docking conformation to further optimize the binding conformation between the drug and the target.

[0033] In an optional embodiment, step S3 also includes: molecular dynamics simulation: performing molecular dynamics simulation to verify the binding stability of the drug and the target and analyze the dynamic changes of the interaction.

[0034] Free energy calculation: Use MM / PBSA, MM / GBSA and other methods to calculate the binding free energy and further verify the affinity between the drug and the target.

[0035] In an optional embodiment, step S5 further includes:

[0036] S51. Tissue sample processing: Collect tumor tissue samples from pancreatic cancer patients, screen out tissue samples with potential drug target characteristics, and maintain tissue activity;

[0037] Tissue digestion: Cut the tumor tissue into small pieces, digest it in a digestive enzyme solution, and filter and collect the cell suspension;

[0038] Cell culture: Mix the cell suspension with matrix gel, add it dropwise to the culture plate, and add organoid culture medium after solidification;

[0039] S52. Organoid culture; Initial culture: Culture in organoid culture medium for 7-14 days, during which time the culture medium is replaced.

[0040] Subculture: When organoids grow to a certain size, they are subcultured by mechanical or chemical methods;

[0041] S53, high-throughput drug sensitivity testing; drug processing: select and prepare drug libraries to ensure accurate drug concentrations.

[0042] Organoid seeding: Dissociate organoids into single cells or small clumps and distribute them into 96-well or 384-well culture plates.

[0043] Drug addition: The automated system adds drug solutions of different concentrations to each well and sets the control group

[0044] S54. Data collection and analysis; Survival rate detection: After 48-72 hours of culture, use a cell viability reagent to detect the survival rate of organoids and read the data using a reader.

[0045] Data processing: Use software to analyze data, draw drug concentration-effect curves, and calculate IC50 values.

[0046] Data verification: Select some drugs with significant effects for repeated experiments to verify the reliability of the results.

[0047] Compared with the prior art, the present invention has the following beneficial technical effects:

[0048] (1) Discovery of pancreatic cancer population-specific targets: Based on the open-source pancreatic cancer population characteristic gene mutation data and copy number variation data, characteristic markers of the pancreatic cancer population are analyzed and screened; combined with the drug sensitivity data of the GDSC database and the gene mutation and gene expression data of the CMP database, characteristic markers (potential drug targets) that are positively correlated with the sensitivity of non-pancreatic cancer drugs (alternative drugs) are further screened, thereby providing support for the expansion of the drug's pancreatic cancer indications.

[0049] (2) Rapid screening of drugs targeting pancreatic cancer targets: Predict the affinity of candidate drugs for potential drug targets through computer simulation and molecular docking technology; establish and optimize an in vitro pancreatic cancer organoid model, and conduct high-throughput drug sensitivity testing to verify the actual sensitivity of the drug.

[0050] (3) Screening of biomarkers related to drug sensitivity: Based on the open-source gene mutation data, gene expression data, and drug sensitivity data of pancreatic cancer samples, through correlation analysis, the association between specific gene mutations or abnormal expressions and drug sensitivity is clarified, and biomarkers that are highly correlated with drug sensitivity are screened out, providing a basis for personalized drug treatment of pancreatic cancer.

[0051] (4) The present invention uses computer-aided rapid screening of new targets for pancreatic cancer and rapid discovery of drugs with potential therapeutic effects. Through computer simulation and molecular docking technology and organoid high-throughput drug sensitivity detection models, it can reduce dependence on manual design and animal experiments, thereby reducing drug development costs and time. It explores the potential target groups of drugs and simultaneously develops companion diagnostic technologies for predicting the drug effects of new small molecule drugs, which can provide support for personalized precision medication and improve clinical treatment effects. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 Schematic diagram of the screening method in an embodiment of the present invention. DETAILED DESCRIPTION

[0053] Example 1

[0054] like Figure 1 As shown, the present invention provides a screening method for expanding the indication of pancreatic cancer of anti-tumor drugs, comprising the following specific steps:

[0055] Step 1: Pancreatic cancer marker screening and target identification

[0056] (1) Data Collection

[0057] a) Select antimetabolite drugs (standard indication is not pancreatic cancer) as the alternative drug type. Collect the drug sensitivity test data (IC50 values) of antimetabolite drugs in pancreatic cancer cell lines through the GDSC database, and collect the maximum plasma drug concentration (Cmax values) of the corresponding drugs through the DrugBank database, and compare the two. When IC50 < Cmax, it is regarded as drug-sensitive (Y); when IC50 > Cmax, it is regarded as drug-insensitive (N). Statistically analyze the drug-sensitive proportion of cell lines and the effective rate of drugs, and screen cell lines with a drug-sensitive proportion greater than 70% as the sensitive sample group (n = 50), and cell lines with a drug-sensitive proportion less than 30% as the drug-resistant sample group (n = 50); Screen drugs with an effective rate greater than 50% as alternative drugs for affinity prediction, as follows:

[0058] Drug 1 Drug 2 Drug 3 Drug 4 Drug 5 …… Sensitive ratio Cell Line 1 Y Y N Y Y …… 95% Cell Line 2 N Y Y N Y …… 88% Cell Line 3 N Y N Y N …… 23% Cell Line 4 Y N Y N Y …… 77% Cell Line 5 N N N Y N …… 15% …… …… …… …… …… …… …… …… Efficiency 45% 69% 36% 85% 92% ……

[0059] b) Organize the genomic data of the screened sensitive sample group and drug-resistant sample group, and query the gene mutation data and gene expression data corresponding to pancreatic cancer cell lines through the CMP database;

[0060] c) Screen genes with specific mutations or copy number variations in the pancreatic cancer population through the TCGA database as the control basis for confirming potential drug targets.

[0061] (2) Bioinformatics analysis

[0062] a) Use dplyr to detect the gene mutation data of the sensitive sample group and drug-resistant sample group, identify high-frequency mutated genes, compare them with the genes with specific mutations in the pancreatic cancer population screened through the TCGA database, prioritize the overlapping genes of the two, and evaluate the impact of the mutation on gene function through functional prediction tools (such as SIFT, PolyPhen), and screen genes related to tumor cell metabolism function for correlation analysis;

[0063] b) Use DESeq2 or edgeR to perform differential expression analysis on the gene expression data of the sensitive sample group and drug-resistant sample group, combine the expression of the gene in normal cells and the copy number variation in the TCGA database, determine the gene expression situation (low expression or high expression) for correlation analysis.

[0064] (3) Correlation analysis

[0065] a) Integrate the gene data of the sensitive sample group and drug-resistant sample group, and perform a correlation analysis on the distribution of mutated genes and abnormally expressed genes in the sensitive sample group and drug-resistant sample group according to the Fisher's exact test method, and screen out mutated genes and highly expressed genes associated with drug sensitivity, using p≥0.05 as the exclusion threshold. As follows:

[0066]

[0067] b) Linear correlation analysis is used to analyze the Pearson correlation coefficient of each drug sensitivity data in the candidate drugs with the mutant genes and abnormally expressed genes that have been screened for potential association (P < 0.05), and to identify genes with strong correlation with drug sensitivity as potential drug targets. In the data queue, sensitivity and resistance are marked as 1 and 0, respectively, gene mutants and wild types are marked as 1 and 0, respectively, and high and low gene expressions are marked as 1 and 0, respectively. The analysis results are expressed as Pearson correlation coefficients, ranging from -1 to 1, 0 indicates no correlation, 1 indicates a complete positive correlation, and -1 indicates a complete negative correlation. Among them, 0-0.1: indicates no correlation; 0.1-0.3: indicates a weak correlation; 0.3-0.5: indicates a moderate degree of correlation; >0.5: indicates a strong correlation.

[0068] For example, drug 1:

[0069]

[0070] c) Use multiple testing correction (such as Bonferroni or FDR) to control the false discovery rate.

[0071] d) The mutant genes and highly expressed genes with strong correlation (>0.5) with each drug are screened and summarized. The mutant gene cohorts with higher statistical proportions (including positive and negative correlations) can be used as the screening basis for guiding the use of this type of drug, and the highly expressed genes with strong statistical positive correlation can be used as potential drug targets for the next step of molecular affinity prediction.

[0072] Step 2: Prediction of drug-target affinity

[0073] (1) Data Collection

[0074] a) According to the drug target name, obtain the three-dimensional structure of the target protein from the PDB database (https: / / www.rcsb.org / ) or through homology modeling and other methods.

[0075] b) According to the candidate drug name, obtain the three-dimensional structure of the drug molecule from the Pubchem database (https: / / pubchem.ncbi.nlm.nih.gov / ), usually in SDF or Mol2 format, which can be converted to PDB format using tools such as OpenBabel.

[0076] (2) Data preprocessing

[0077] a) Protein preprocessing: Use AutoDockTools (ADT) to open the protein PDB file, add missing hydrogen atoms, and repair missing side chains and residues; unless water molecules play an important role in the binding pocket, water molecules generally need to be deleted; add polar hydrogen atoms to the protein; if flexible docking is required, select the flexible chain in the protein.

[0078] Specific operations:

[0079] 1) Open ADT and load the protein PDB file.

[0080] 2) Select Edit>Hydrogens>Add>All Hydrogens>Yes>OK.

[0081] 3) Select Edit>Hydrogens>Merge Non-polar>OK.

[0082] 4) Select Grid>Macromolecule>Choose>Select the loaded protein PDB file>SelectMolecule.

[0083] 5) Select Grid>Macromolecule>Save>Save as PDBQT file.

[0084] b) Preprocessing of drug molecules: Use chemical software (such as Chem3D) to optimize the geometric structure of the ligand and generate a low-energy conformation; add polar hydrogen atoms to the ligand; define rotatable bonds in the ligand to simulate the flexibility of the ligand during docking.

[0085] Specific operations:

[0086] 1) Open ADT and load the ligand PDB file.

[0087] 2) Select Ligand>Input>Open>Select ligand PDB file.

[0088] 3) Select Ligand>Torsion Tree>Detect Root>Accept Root.

[0089] 4) Select Ligand > Torsion Tree > Choose Torsions > Select Rotatable Bond > Done.

[0090] 5) Select Ligand>Output>Save as PDBQT>Save as PDBQT file.

[0091] (3) Molecular docking

[0092] a) Define the docking site: Identify the active site or target region in the protein, either through known ligand binding sites or structure-based predictions.

[0093] Specific operations:

[0094] 1) In ADT, select Grid > GridBox.

[0095] 2) Drag the grid box on the displayed protein structure to adjust the size and position to ensure that the active site is included.

[0096] 3) Select the atom type to be calculated in Grid>Set Map Types and save it as a .gpf file.

[0097] b) Set docking parameters: Set docking parameters according to the selected software, including docking mode, search algorithm, scoring function, etc.

[0098] Specific operations:

[0099] 1) In ADT, select Docking>Macromolecule>Set Rigid Filename>Select the protein PDBQT file.

[0100] 2) Select Docking>Ligand>Choose>Select ligand PDBQT file.

[0101] 3) Select Docking>Search Parameters>Genetic Algorithm> to set the above genetic algorithm parameters.

[0102] 4) Select Docking>Output>LAMMPS Settings>Save as DPF>Save the docking configuration file.

[0103] c) Run docking calculations: dock the drug molecule into the protein target and generate multiple docking conformations and scores.

[0104] In the command line, run the following command to start the connection:

[0105] autodock4-p<configuration.dpf> -l<output.dlg>

[0106] in<configuration.dpf> For the generated docking configuration file,<output.dlg> To output the log file.

[0107] (4) Results analysis

[0108] a) Analyze the docking results

[0109] Output file (.dlg): contains all docking results, including scores, binding conformations, etc.

[0110] Scoring function: Evaluate the binding energy between ligand and target and select the conformation with the lowest score.

[0111] b) Visual analysis

[0112] Specific operations:

[0113] 1) In ADT, select Analyze>Docking Results>Load>Select output file.dlg.

[0114] 2) Select Analyze>Conformations>Play>Play the bound conformations one by one.

[0115] 3) Use options such as Analyze>H-bonds>Show H-bonds to analyze the interaction between ligand and protein.

[0116] (5) Verification screening

[0117] a) Molecular dynamics simulation: Molecular dynamics simulation is performed to verify the binding stability between drugs and targets and analyze the dynamic changes of the interaction.

[0118] b) Free energy calculation: Use MM / PBSA, MM / GBSA and other methods to calculate the binding free energy and further verify the affinity between the drug and the target.

[0119] c) Structural optimization: Based on the analysis results, select candidate drug molecules with higher affinity for organoid drug sensitivity testing.

[0120]

[0121] Step 3: High-throughput drug sensitivity testing of organoids

[0122] (1) Tissue sample processing

[0123] a) Sample collection: Tumor tissue samples were collected from pancreatic cancer patients, tissue samples with potential drug target characteristics were screened (n = 100), and tissue activity was maintained;

[0124] b) Tissue processing

[0125] Specific operations:

[0126] 1) Washing: The tumor tissue was placed under sterile conditions and washed several times with PBS (phosphate buffered saline) to remove blood and other impurities.

[0127] 2) Cutting: Use scissors or a scalpel to cut the tissue into small pieces of 1-2 mm.

[0128] 3) Digestion: Place the cut tissue blocks in a digestive enzyme solution (such as a mixed solution of collagenase, trypsin and DNase) and digest at 37°C for 1-2 hours, stirring gently every 15 minutes.

[0129] 4) Filtration: After digestion is complete, filter through a 100 μm filter to remove undigested large pieces of tissue and collect the filtrate.

[0130] c) Cell culture

[0131] Specific operations:

[0132] 1) Centrifugation and resuspension: Centrifuge the filtrate, discard the supernatant, and resuspend the cell pellet in culture medium.

[0133] 2) Mixing and dropping: Mix the cell suspension with matrix gel (such as Matrigel) and drop it into the culture plate, with each drop being about 20-50 μl, to form a semi-solid gel.

[0134] 3) Incubation: Place the culture plate containing the cells in a 37°C incubator and incubate until the gel solidifies (approximately 10-15 minutes).

[0135] 4) Culture medium addition: Add appropriate amount of organoid culture medium and continue culturing.

[0136] (2) Organoid culture

[0137] a) Initial culture: Culture in organoid culture medium for 7-14 days, during which time the medium is changed.

[0138] b) Subculture: When organoids grow to a certain size, they are subcultured by mechanical or chemical methods.

[0139] (3) High-throughput drug sensitivity testing

[0140] a) Drug processing: Prepare solutions based on the molecular properties of the screened candidate drugs to ensure accurate drug concentration.

[0141] b) Organoid seeding: Organoids are dissociated into single cells or small clumps and distributed into 96-well or 384-well culture plates.

[0142] c) Drug addition: The automated system adds drug solutions of different concentrations into each well and sets up a control group.

[0143] (4) Data collection and analysis

[0144] a) Survival rate detection: After culturing for a certain period of time (usually 48 - 72 hours), use cell viability reagents (such as CellTiter - Glo, MTS, MTT, etc.) to detect the survival rate of organoids in each well; read the luminescence or absorbance values of each well through an automated microplate reader, and calculate the organoid survival rate at each drug concentration.

[0145] b) Data processing: Use professional software (such as GraphPad Prism) to process and analyze the experimental data, draw the drug concentration - effect curve, calculate the half - maximal inhibitory concentration (IC50), collect the maximum plasma drug concentration (Cmax value) of the corresponding drug through the DrugBank database, and compare the two. When IC50 < Cmax, it is regarded as drug - sensitive (Y); when IC50 > Cmax, it is regarded as drug - insensitive (N). By comparing the effects of different drugs on the survival rate of organoids, screen out drugs with high activity according to the sensitivity rate, and use them as drugs for expandable pancreatic cancer indications. As follows:

[0146] Drug 1 Drug 2 Drug 3 Drug 4 Drug 5 …… Organoid 1 N Y N Y Y …… Organoid 2 N Y Y Y N …… Organoid 3 Y N N N N …… Organoid 4 N Y N N N …… Organoids 5 Y Y N Y Y …… …… …… …… …… …… …… …… Sensitivity 24% 89% 18% 67% 48% ……

[0147] c) Data verification: Select some drugs with significant effects for repeated experiments to verify the reliability of the results.

[0148] There are the following disadvantages in the prior art. Narrow range of drug indications: There is a lack of screening of drug molecules for characteristic markers of the pancreatic cancer population. Many non - pancreatic cancer drugs are only effective for specific gene mutations or specific biomarker populations, restricting the scope of drug application. Limitations in drug discovery methods: Traditional drug screening methods mainly rely on traditional empirical judgment and cannot exclude drugs with poor target affinity as much as possible in the early stage; experimental methods mainly rely on in vitro cell lines and animal models and cannot simulate the tumor microenvironment and heterogeneity, resulting in the failure of many drugs effective in the early - stage screening in clinical trials. Unknown drug - sensitivity - related markers: Pancreatic cancer has a high degree of genetic heterogeneity, resulting in significant differences in the responses of different patients to the same drug, and the problem of drug resistance follows.

[0149] After using the method of the present invention, rapid screening of new targets for pancreatic cancer can be achieved through computer - aided means, and drugs with potential therapeutic effects can be quickly discovered; through computer simulation, molecular docking technology, and high - throughput organoid drug - sensitivity detection models, the dependence on manual design and animal experiments can be reduced, thereby reducing the cost and time of drug research and development; explore the potential target groups of drugs, and simultaneously develop drug - effect prediction companion diagnostic technologies for new small - molecule drugs, which can provide support for personalized and precise drug use and improve the clinical treatment effect.

[0150] The embodiments of the present invention are described in detail above with reference to the accompanying drawings, but the present invention is not limited thereto, and various changes can be made within the knowledge scope of technicians in the relevant technical field without departing from the purpose of the present invention.

Claims

1. A screening method for expanding the indication of pancreatic cancer for anti-tumor drugs, characterized in that: The specific steps include: S1. Screening of pancreatic cancer markers and target identification based on open source databases; S2. Predict drug-target affinity based on the screened pancreatic cancer markers and targets; S3. Conduct simulation experiments on the drug molecules with higher predicted affinity; S4. Screen out candidate drug molecules with higher affinity based on the experimental results; S5. Conduct high-throughput drug sensitivity testing in organoids on the candidate drug molecules screened in S4; S6. Obtain effective drug molecules.

2. The method for screening anti-tumor drugs for expanding the indication of pancreatic cancer according to claim 1, characterized in that: Step S1 identifies new potential drug targets for pancreatic cancer populations through bioinformatics analysis, drug sensitivity association analysis, and functional annotation based on open source databases.

3. The screening method for expanding the indication of pancreatic cancer for anti-tumor drugs according to claim 2, characterized in that: Bioinformatics analysis includes gene mutation analysis and gene expression analysis.

4. The method for screening anti-tumor drugs for expanding the indication of pancreatic cancer according to claim 2 or 3, characterized in that: Step S1 also includes: S11. Data collection; With reference to the types of candidate drugs, the standard indications of the selected drugs do not include pancreatic cancer. The drug sensitivity test data, blood drug concentration data and genetic data of pancreatic cancer cell lines that have completed the drug sensitivity test of related types are collected; the drug sensitivity test data are derived from the GDSC database, the maximum blood drug concentration of the drug is derived from the DrugBank database, and the gene mutation data and gene expression data of the corresponding cell lines are derived from the CMP database; The characteristic gene mutation data and copy number variation data of pancreatic cancer population were derived from the TCGA database, and the gene expression data of normal intestinal cells were derived from the THPA database; S12, bioinformatics analysis; Use dplyr to screen for high-frequency gene mutations, use functional prediction tools to evaluate the impact of mutations on gene function, and screen genes related to tumorigenesis for association analysis; Use DESeq2 or edgeR to perform differential expression analysis to compare the gene expression differences between pancreatic cancer samples and normal samples. Combine the gene expression in normal cells and the copy number variation in the TCGA database to determine the gene expression for association analysis; S13, association analysis; Integrate the genetic data of the sensitive sample group and the drug-resistant sample group, analyze the correlation through the chi-square test, and screen out the mutant genes and abnormally expressed genes associated with drug sensitivity; use linear correlation to analyze the Pearson correlation coefficient of drug sensitivity data with variables such as mutant genes and abnormally expressed genes, and identify the genes most prominently associated with drug sensitivity as potential drug targets; use multiple test correction (such as Bonferroni or FDR) to control the false discovery rate; S14, functional annotation; Ensembl and RefSeq were used to perform functional annotations on differentially expressed genes and mutated genes. The role and potential mechanism of these genes in tumorigenesis were identified by referring to the characteristic gene mutation data and copy number variation data of pancreatic cancer populations. Priority sorting was performed based on association analysis data to screen out new potential drug targets.

5. The method for screening anti-tumor drugs for expanding the indication of pancreatic cancer according to claim 4, characterized in that: The types of alternative drugs referenced include alkylating drugs, antimetabolites, antibiotics, plants, hormones, platinum compounds, and targeted drugs.

6. The method for screening anti-tumor drugs for expanding the indication of pancreatic cancer according to claim 1, characterized in that: Step S2 also includes: S21. Data collection; According to the drug target name, the three-dimensional structure of the target protein is obtained from the PDB database or through homology modeling and other methods; According to the candidate drug names, the three-dimensional structure of the drug molecule is obtained from the Pubchem database; S22, data preprocessing; Protein preprocessing: Use AutoDockTools to open protein PDB files, add missing hydrogen atoms, repair missing side chains and residues; add polar hydrogen atoms to proteins; Pretreatment of drug molecules: using chemical software to optimize the geometric structure of ligands and generate low-energy conformations; adding polar hydrogen atoms to ligands; S23, molecular docking; Define docking sites: Identify active sites or target regions in proteins, either through known ligand binding sites or structure-based predictions; Set docking parameters: Set docking parameters according to the selected software, including docking mode, search algorithm, and scoring function; Run docking calculations: dock drug molecules into protein targets, generate multiple docking conformations and scores; S24. Result analysis; evaluate docking results: evaluate the affinity between the drug and the target according to the docking scoring function, and select the conformation with a higher score; Visual analysis: Use visualization software to analyze docking results and examine the interaction pattern between drugs and targets; Energy minimization: Minimize the energy of the optimal docking conformation and optimize the binding conformation between the drug and the target.

7. The method for screening anti-tumor drugs for expanding the indication of pancreatic cancer according to claim 1, characterized in that: Step S3 also includes: Molecular dynamics simulation: Conduct molecular dynamics simulation to verify the binding stability between drugs and targets and analyze the dynamic changes of interactions. Free energy calculation: MM / PBSA and MM / GBSA methods were used to calculate the binding free energy to further verify the affinity between the drug and the target.

8. The method for screening anti-tumor drugs for expanding the indication of pancreatic cancer according to claim 1, characterized in that: Step S5 also includes: S51. Tissue sample processing: Collect tumor tissue samples from pancreatic cancer patients, screen out tissue samples with potential drug target characteristics, and maintain tissue activity; Tissue digestion: Cut the tumor tissue into small pieces, digest it in a digestive enzyme solution, and filter and collect the cell suspension; Cell culture: Mix the cell suspension with matrix gel, add it dropwise to the culture plate, and add organoid culture medium after solidification; S52, organoid culture; Initial culture: Culture in organoid culture medium for 7-14 days, during which time the medium is changed; Subculture: When organoids grow to a predetermined size, they are subcultured by mechanical or chemical methods; S53, high-throughput drug susceptibility testing; Drug handling: Select and prepare drug libraries to ensure accurate drug concentrations; Organoid seeding: Dissociate organoids into single cells or small clumps and distribute them into 96-well or 384-well culture plates; Drug addition: The automated system adds drug solutions of different concentrations to each well and sets up a control group; S54, data collection and analysis; Survival rate detection: After 48-72 hours of culture, use a cell viability reagent to detect the survival rate of organoids and read the data using a reader; Data processing: Use software to analyze data, draw drug concentration-effect curves, and calculate IC50 values; Data verification: Select some drugs with significant effects for repeated experiments to verify the reliability of the results.